Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods g | ...

Compounding pharmacies make their own versions of weight loss drugs at a fraction of the price but there are some drawbacks.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The agency wants applicants to demystify their algorithms and provide specific details about what the models do, how they’re ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, ...

Bryan Johnson, a tech entrepreneur, has stopped using rapamycin, a drug not approved for anti-aging by the FDA, following ...

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

Novartis faces short-term challenges with patent expirations but shows long-term growth potential. Click here to read why I ...